| Issue |
Section |
Title |
File |
| Vol 90, No 1 (2014) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Long-term therapy of severe acne: selection of doses and administration schemes for systemic isotretinoin |
(Rus)
|
| Vol 90, No 4 (2014) |
CLINICAL CASE REPORTS |
A case of a combination of Crocker - Adamson follicular spinulosa, lichen acuminatus and Little - Lassueur syndrome |
(Rus)
|
| Vol 91, No 1 (2015) |
ORIGINAL STUDIES |
Endothelial dysfunction and its treatment in psoriasis patients |
(Rus)
|
| Vol 91, No 1 (2015) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Microbial eczema: up-to-date topical treatment with silver sulfathiazole |
(Rus)
|
| Vol 92, No 3 (2016) |
CLINICAL CASE REPORTS |
A case of localized bullous scleroderma |
(Rus)
|
| Vol 92, No 3 (2016) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Using clobetasol propionate in the form of a shampoo for the treatment of patients suffering from psoriasis localized in the scalp area |
(Rus)
|
| Vol 92, No 5 (2016) |
CLINICAL PRACTICE GUIDELINES |
Strategy “treat to target” for patients with psoriasis. Relevant issues to biological therapy persistence |
(Rus)
|
| Vol 92, No 5 (2016) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Selective intracellular inhibition of signalling pathways - new direction in systematic treatment of psoriasis patients |
(Rus)
|
| Vol 93, No 1 (2017) |
ORIGINAL STUDIES |
Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients |
(Rus)
|
| Vol 93, No 5 (2017) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis |
(Rus)
|
| Vol 93, No 5 (2017) |
ORIGINAL STUDIES |
Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis |
(Rus)
|
| Vol 94, No 3 (2018) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Psoriasis: clinical and epidemiological features and therapy issues |
(Rus)
|
| Vol 94, No 5 (2018) |
REVIEWS |
Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis |
(Rus)
|
| Vol 95, No 2 (2019) |
ORIGINAL STUDIES |
Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis |
(Rus)
|
| Vol 95, No 3 (2019) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext |
(Rus)
|
| Vol 95, No 4 (2019) |
CLINICAL PRACTICE GUIDELINES |
Dermatoscopy in the diagnosis of pigmented nevi |
(Rus)
|
| Vol 95, No 4 (2019) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Results of the long-term observational noninterventional prospective study BODYGUARD in psoriasis patients |
(Rus)
|
| Vol 95, No 5 (2019) |
DRUG TREATMENT IN DERMATOVENEROLOGY |
Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis |
(Rus)
|
| Vol 97, No 5 (2021) |
REVIEWS |
Revisiting the question of psoriasis classification |
(Rus)
|
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).